WP
KLRS

Woodline Partners’s Kalaris Therapeutics KLRS Stock Holding History

Woodline Partners’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$577K Hold
100,000
– – ﹤0.01% 944
2025
Q4 		$844K Sell
100,000
-141,102
-59% -$902K ﹤0.01% 852
2025
Q3 		$1.39M Buy
+241,102
New +$797K 0.01% 774
2025
Q2 		– Sell
-21,519
Closed -$173K – 1086
2025
Q1 		$173K Buy
21,519
+1,873
+10% +$18.3K ﹤0.01% 881
2024
Q4 		$190K Buy
+19,646
New +$297K ﹤0.01% 908
2024
Q1 		– Sell
-109,174
Closed -$1.71M – 655
2023
Q4 		$1.71M Buy
109,174
+19,319
+22% +$762K 0.02% 386
2023
Q3 		$4.44M Buy
89,855
+14,724
+20% +$1M 0.05% 327
2023
Q2 		$5.88M Buy
75,131
+31,653
+73% +$3.01M 0.07% 268
2023
Q1 		$3.94M Sell
43,478
-3,787
-8% -$482K 0.05% 324
2022
Q4 		$5.58M Hold
47,265
– – 0.07% 297
2022
Q3 		$8.58M Hold
47,265
– – 0.12% 217
2022
Q2 		$4.24M Hold
47,265
– – 0.07% 285
2022
Q1 		$7.34M Hold
47,265
– – 0.12% 206
2021
Q4 		$14.1M Sell
47,265
-16,194
-26% -$7.51M 0.2% 143
2021
Q3 		$36.6M Buy
63,459
+1,464
+2% +$678K 0.6% 38
2021
Q2 		$28.1M Buy
61,995
+10,694
+21% +$5.52M 0.52% 46
2021
Q1 		$27.6M Buy
51,301
+6,089
+13% +$5.12M 0.61% 50
2020
Q4 		$40M Sell
45,212
-6,571
-13% -$5.06M 1.06% 25
2020
Q3 		$32.8M Buy
+51,783
New +$35.4M 1.07% 28

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Woodline Partners's KLRS Position: Q1 2026 in Review

Woodline Partners held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 100,000 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Woodline Partners first reported a position in KLRS in Q3 2020 and has held it in 19 quarters since. The position peaked at $40M in Q4 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Woodline Partners held 100,000 shares of Kalaris Therapeutics worth $577K as of Q1 2026.
  • Woodline Partners left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #944 holding.
  • Woodline Partners first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • Woodline Partners's Kalaris Therapeutics position peaked at $40M in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.